Edgestream Partners L.P. acquired a new position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 27,349 shares of the biopharmaceutical company’s stock, valued at approximately $1,286,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Hanseatic Management Services Inc. bought a new position in shares of Sage Therapeutics during the 2nd quarter worth about $34,000. MetLife Investment Management LLC bought a new position in shares of Sage Therapeutics during the 1st quarter worth about $34,000. Headlands Technologies LLC bought a new position in shares of Sage Therapeutics during the 2nd quarter worth about $115,000. Tower Research Capital LLC TRC increased its position in shares of Sage Therapeutics by 257.1% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,103 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 2,234 shares in the last quarter. Finally, Dark Forest Capital Management LP acquired a new stake in shares of Sage Therapeutics during the 1st quarter worth about $134,000. 89.68% of the stock is owned by institutional investors.
Sage Therapeutics Price Performance
Sage Therapeutics stock opened at $19.72 on Tuesday. Sage Therapeutics, Inc. has a fifty-two week low of $16.51 and a fifty-two week high of $59.99. The company’s 50 day simple moving average is $19.61 and its 200 day simple moving average is $33.26. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -1.80 and a beta of 1.12.
Wall Street Analyst Weigh In
About Sage Therapeutics
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases.
- Five stocks we like better than Sage Therapeutics
- What is the FTSE 100 index?
- Safeguard your portfolio with these three bargain stocks
- Insider Buying Explained: What Investors Need to Know
- Membership clubs gain leverage for the consumer rebound
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.